EDWARD WYNN LLC – Trademark Portfolio

Entity Type: 16

EDWARD WYNN LLC holds 30 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 29 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 10 trademarks are registered and 1 is pending. Notable registered marks include LIVER DEFENDER. The owner is based in ARCADIA, CA.

308 SOUTH FIRST AVENUE

#D

ARCADIA, CA 91006

30 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Page 1 of 2 (30 results)

Trademark Classifications

EDWARD WYNN LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (29 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

Frequently Asked Questions

How many trademarks does EDWARD WYNN LLC have?

EDWARD WYNN LLC has 30 U.S. trademarks filed with the USPTO. Of these, 10 registered, 1 pending, 19 cancelled.

What trademark classes does EDWARD WYNN LLC file in?

EDWARD WYNN LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are EDWARD WYNN LLC's most well-known trademarks?

EDWARD WYNN LLC's registered trademark portfolio includes well-known marks such as LIVER DEFENDER. These are among 10 currently registered trademarks in the portfolio.

What is EDWARD WYNN LLC's trademark registration success rate?

EDWARD WYNN LLC has a 34% trademark registration rate, with 10 out of 29 resolved applications resulting in successful registration. Currently, 1 application is pending review.